FCER2 Specific Neutra™ Antibody Products

FCER2, also known as CD23, plays a pivotal role in modulating immune responses. Existing in membrane-bound or soluble forms, FCER2 is widely distributed on the surfaces of immune cells and is involved in regulating processes such as IgE levels, immune cell activation, and antigen presentation.

Structure and Expression of FCER2

FCER2 belongs to the C-type lectin family, consisting of a 45 kDa subunit. The extracellular portion consists of three regions: the alpha-helical stalk region mediating trimer formation, the lectin head binding to IgE, and the RGD sequence modifying integrin-binding proteins. FCER2 is primarily expressed in immune cells such as B cells, T cells, monocytes, and polymorphonuclear leukocytes, regulated by various stimuli.

Fig.1 CD23 structure.¹

Primary Functions of FCER2

Fig.2 CD23 function.²

As a receptor for Immunoglobulin E (IgE), FCER2 plays a crucial role in regulating immune responses. Its main functions include.

• Modulation of IgE Levels: FCER2 forms complexes with IgE, regulating the levels of IgE in the serum, and influencing the intensity and duration of IgE-mediated immune responses.
• Immune Cell Activation: IgE-ICs are preferentially captured by FCER2 on B cells, regulating serum IgE and preventing effector cell activation, thereby modulating the process of immune responses.
• Antigen Presentation: FCER2 participates in the process of antigen presentation, facilitating the recognition and processing of antigens by immune cells. On the surface of B cells, FCER2 binds to IgE-antigen complexes, promoting antigen recognition and internalization.
• Other Functions: FCER2 can act as a C-type lectin, promoting antibacterial immunity, or bind to sialylated IgG complexes, acting as Fcγ receptors.

Fig.3 Mechanisms of IgE targeting CD23.³

FCER2 and Diseases

FCER2 plays a crucial role in the development of various diseases, with its abnormal expression and dysfunction closely associated with the occurrence and progression of the following conditions.

• Allergic Diseases: FCER2's abnormal expression and activation may lead to the occurrence and development of allergic diseases such as asthma and allergic rhinitis, and the inhibition of FCER2 has become a potential strategy for treating these diseases.
• Cancer: High levels of FCER2 expression are associated with the development and prognosis of certain tumors. Abnormal expression of FCER2 in tumors such as lymphoma and plasma cell myeloma may indicate tumor progression and poor prognosis.
• Autoimmune Inflammatory Diseases: Abnormal expression and function of FCER2 may be correlated with autoimmune inflammatory diseases. Soluble FCER2 is considered a useful biomarker for rheumatoid arthritis, and the regulation of FCER2 may become a new approach to treating these diseases.

Fig.4 IgE-IC processing by CD23.³

Our Services

Creative Biolabs is dedicated to providing high-quality antibody production services utilizing advanced technologies and platforms. Clients can choose antibody types suitable for their research needs and customize antibody products with specific structures and properties. Through our robust and cutting-edge neutralizing antibody and recombinant antibody technology platform, clients can obtain high-quality, efficient antibody products, and optimal customized solutions. Please do not hesitate to contact us for personalized services and support.

REFERENCES

1. Sutton, Davies, et al. "IgE Antibodies: From Structure to Function and Clinical Translation." Antibodies 8.19 (2019): 3390.
2. Acharya, Borland, et al. "CD23/FcRII: molecular multi-tasking." Journal of Translational Immunology 162 (2010): 12-23.
3. Engeroff, Vogel, et al. "The role of CD23 in the regulation of allergic responses." Allergy 76 (2021): 1981-1989.